A recent study compared the effectiveness of stereotactic ablative body radiotherapy with conventional full fractionated radiotherapy in prolonging time to local failure in patients with inoperable stage I non-small cell lung cancer. READ MORE
One assay test reveals statistically lower levels of PD-L1 expression than the others.
Results show that hypofractionated radiation therapy may be a better treatment option for patients with non-small cell lung cancer.
Using a web application developed by French researchers may help clinicans to better manage follow-up for patients with lung cancer.
Benefits of Using Comparative-Effectiveness Data in Lieu of Clinical Trials to Support Treatment Strategies
Clinicians will be required to use observational data to make decisions.
A recent study compared the effectiveness of stereotactic ablative body radiotherapy with conventional full fractionated radiotherapy in prolonging time to local failure in patients with inoperable stage I non-small cell lung cancer.
Despite the majority of radiation oncologists administering the NCCN guideline-recommended thoracic radiotherapy schedule to patients with small-cell lung cancer, great variability still exists in dosing and fractionation.
A liquid biopsy that measures circulating lung tumor DNA at the end of treatment identifies patients with early NSCLC with a poor prognosis.
Radiation therapy, when given in conjunction with a newly formulated chemotherapy regimen, improves survival rates up to 12 months for patients with inoperable non-small cell lung cancer.
Research in Review
Increasing the standard dose of an ALK inhibitor for the treatment of NSCLC improves objective response rates by 9% with limited additional toxicity.
According to recent research published in the International Journal of Radiation Oncology, which form of therapy is effective in older patients with early stage lung cancer?
Stereotactic body radiation therapy is a safe treatment for patients aged 80 years or older with early-stage lung cancer.